Showing 1281-1290 of 23044 results for "".
Diagnosing IBD: Is It IBD or Something Else? Can You Tell?
https://reachmd.com/programs/cme/diagnosing-ibd-is-it-ibd-or-something-else-can-you-tell/51480/Explore IBD from diagnosis to remission with practical cases, treatment strategies, and a treat-to-target approach for optimal patient outcomes.IBD Immunopathogenesis: Do You Know What You're Blocking?
https://reachmd.com/programs/cme/ibd-immunopathogenesis-do-you-know-what-youre-blocking/51482/Explore IBD from diagnosis to remission with practical cases, treatment strategies, and a treat-to-target approach for optimal patient outcomes.Case Review: Can You Crack This IBD Case?
https://reachmd.com/programs/cme/case-review-can-you-crack-this-ibd-case/51484/Explore IBD from diagnosis to remission with practical cases, treatment strategies, and a treat-to-target approach for optimal patient outcomes.Latest TROP2 ADC Approval for HR+ HER2- Metastatic Breast Cancer
https://reachmd.com/programs/medical-industry-feature/latest-trop2-adc-approval-for-hr-her2-metastatic-breast-cancer/29175/There’s been recent progress with antibody-drug conjugates (ADCs) for HER2-negative breast cancers,1-3 and most recently, patients with metastatic HR+ HER2- breast cancer. The phase III TROPION-Breast01 study examined the efficacy and safety of datopotamab deruxtecan-dInk (Dato-DXd) compared to invePractical Perspectives in Myasthenia Gravis #3: Therapeutic Selection and Monitoring Efficacy—Matching Mechanisms to Patients
https://reachmd.com/programs/cme/mg-therapeutic-selection-and-monitoring-efficacy-matching-mechanisms-to-patients/39030/Examine evolving gMG management, from standard therapies to targeted agents, with an emphasis on pediatric care and assessment of treatment response.A Clear Horizon in Plaque Psoriasis: An Update on Investigational Oral Therapies
https://reachmd.com/programs/cme/a-clear-horizon-in-plaque-psoriasis-an-update-on-investigational-oral-therapies/37867/Join Drs. Armstrong and Stein Gold as they evaluate the clinical evidence and potential role of emerging oral systemic therapies in moderate to severe psoriasis.Navigating the Therapeutic Landscape of Platinum-Resistant Ovarian Cancer
https://reachmd.com/programs/cme/navigating-the-therapeutic-landscape-of-platinum-resistant-ovarian-cancer/37667/CDH6 in Focus: Advancing Biomarker-Driven Strategies for Platinum-Resistant Ovarian CancerClinical Evidence: Insights From Early Trials of CDH6-Targeted Therapies
https://reachmd.com/programs/cme/clinical-evidence-insights-from-early-trials-of-cdh6-targeted-therapies/37669/CDH6 in Focus: Advancing Biomarker-Driven Strategies for Platinum-Resistant Ovarian CancerUtility of Stereoelectroencephalography in the Treatment of Drug-Resistant Epilepsy
https://practicalneurology.com/diseases-diagnoses/epilepsy-seizures/utility-of-stereo-electroencephalography-in-the-treatment-of-drug-resistant-epilepsy/48919/Drug-resistant epilepsy, which affects about a third of people with epilepsy, can be effectively treated with epilepsy surgery, leading to seizure freedom in appropriately selected individuals.Data Driving Recent Guideline Updates in Neoadjuvant Therapy for Resectable Melanoma
https://reachmd.com/programs/cme/data-driving-recent-guideline-updates-in-neoadjuvant-therapy-for-resectable-melanoma/36322/Explore guideline-based treatment strategies and clinical data to optimize guideline-concordant care for patients with melanoma in the neoadjuvant, adjuvant, and metastatic settings.